Cargando…

Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds

A growing body of evidence indicates that the anticancer effect of the immune system can be activated by the immunogenic modulation of dying cancer cells. Cancer cell death, as a result of the activation of an immunomodulatory response, is called immunogenic cell death (ICD). This regulated cell dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Amiri, Mina, Molavi, Ommoleila, Sabetkam, Shahnaz, Jafari, Sevda, Montazersaheb, Soheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500939/
https://www.ncbi.nlm.nih.gov/pubmed/37705051
http://dx.doi.org/10.1186/s12935-023-03058-7
_version_ 1785106023111983104
author Amiri, Mina
Molavi, Ommoleila
Sabetkam, Shahnaz
Jafari, Sevda
Montazersaheb, Soheila
author_facet Amiri, Mina
Molavi, Ommoleila
Sabetkam, Shahnaz
Jafari, Sevda
Montazersaheb, Soheila
author_sort Amiri, Mina
collection PubMed
description A growing body of evidence indicates that the anticancer effect of the immune system can be activated by the immunogenic modulation of dying cancer cells. Cancer cell death, as a result of the activation of an immunomodulatory response, is called immunogenic cell death (ICD). This regulated cell death occurs because of increased immunogenicity of cancer cells undergoing ICD. ICD plays a crucial role in stimulating immune system activity in cancer therapy. ICD can therefore be an innovative route to improve anticancer immune responses associated with releasing damage-associated molecular patterns (DAMPs). Several conventional and chemotherapeutics, as well as preclinically investigated compounds from natural sources, possess immunostimulatory properties by ICD induction. Natural compounds have gained much interest in cancer therapy owing to their low toxicity, low cost, and inhibiting cancer cells by interfering with different mechanisms, which are critical in cancer progression. Therefore, identifying natural compounds with ICD-inducing potency presents agents with promising potential in cancer immunotherapy. Naturally derived compounds are believed to act as immunoadjuvants because they elicit cancer stress responses and DAMPs. Acute exposure to DAMP molecules can activate antigen-presenting cells (APCs), such as dendritic cells (DCs), which leads to downstream events by cytotoxic T lymphocytes (CTLs) and natural killer cells (NKs). Natural compounds as inducers of ICD may be an interesting approach to ICD induction; however, parameters that determine whether a compound can be used as an ICD inducer should be elucidated. Here, we aimed to discuss the impact of multiple ICD inducers, mainly focusing on natural agents, including plant-derived, marine molecules, and bacterial-based compounds, on the release of DAMP molecules and the activation of the corresponding signaling cascades triggering immune responses. In addition, the potential of synthetic agents for triggering ICD is also discussed.
format Online
Article
Text
id pubmed-10500939
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105009392023-09-15 Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds Amiri, Mina Molavi, Ommoleila Sabetkam, Shahnaz Jafari, Sevda Montazersaheb, Soheila Cancer Cell Int Review A growing body of evidence indicates that the anticancer effect of the immune system can be activated by the immunogenic modulation of dying cancer cells. Cancer cell death, as a result of the activation of an immunomodulatory response, is called immunogenic cell death (ICD). This regulated cell death occurs because of increased immunogenicity of cancer cells undergoing ICD. ICD plays a crucial role in stimulating immune system activity in cancer therapy. ICD can therefore be an innovative route to improve anticancer immune responses associated with releasing damage-associated molecular patterns (DAMPs). Several conventional and chemotherapeutics, as well as preclinically investigated compounds from natural sources, possess immunostimulatory properties by ICD induction. Natural compounds have gained much interest in cancer therapy owing to their low toxicity, low cost, and inhibiting cancer cells by interfering with different mechanisms, which are critical in cancer progression. Therefore, identifying natural compounds with ICD-inducing potency presents agents with promising potential in cancer immunotherapy. Naturally derived compounds are believed to act as immunoadjuvants because they elicit cancer stress responses and DAMPs. Acute exposure to DAMP molecules can activate antigen-presenting cells (APCs), such as dendritic cells (DCs), which leads to downstream events by cytotoxic T lymphocytes (CTLs) and natural killer cells (NKs). Natural compounds as inducers of ICD may be an interesting approach to ICD induction; however, parameters that determine whether a compound can be used as an ICD inducer should be elucidated. Here, we aimed to discuss the impact of multiple ICD inducers, mainly focusing on natural agents, including plant-derived, marine molecules, and bacterial-based compounds, on the release of DAMP molecules and the activation of the corresponding signaling cascades triggering immune responses. In addition, the potential of synthetic agents for triggering ICD is also discussed. BioMed Central 2023-09-13 /pmc/articles/PMC10500939/ /pubmed/37705051 http://dx.doi.org/10.1186/s12935-023-03058-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Amiri, Mina
Molavi, Ommoleila
Sabetkam, Shahnaz
Jafari, Sevda
Montazersaheb, Soheila
Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
title Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
title_full Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
title_fullStr Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
title_full_unstemmed Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
title_short Stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
title_sort stimulators of immunogenic cell death for cancer therapy: focusing on natural compounds
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500939/
https://www.ncbi.nlm.nih.gov/pubmed/37705051
http://dx.doi.org/10.1186/s12935-023-03058-7
work_keys_str_mv AT amirimina stimulatorsofimmunogeniccelldeathforcancertherapyfocusingonnaturalcompounds
AT molaviommoleila stimulatorsofimmunogeniccelldeathforcancertherapyfocusingonnaturalcompounds
AT sabetkamshahnaz stimulatorsofimmunogeniccelldeathforcancertherapyfocusingonnaturalcompounds
AT jafarisevda stimulatorsofimmunogeniccelldeathforcancertherapyfocusingonnaturalcompounds
AT montazersahebsoheila stimulatorsofimmunogeniccelldeathforcancertherapyfocusingonnaturalcompounds